

USP DI® Volume I, Drug Information for the Health Care Professional

FILE DESCRIPTION

The USP DI® Volume I, Drug Information for the Health Care Professional database is a complete, unbiased source of drug information. It contains medically accepted uses for generic and brand name drug products. File 461 contains more than 800 monographs covering more than 11,000 generic and brand name drugs, grouped by family where appropriate. USP DI is named in federal, and some state, statutes as a resource for unlabeled drug uses, patient consultation, and development of drug utilization review (DUR) criteria under Medicaid.

The information in the USP DI® Volume I database undergoes an approval process unmatched by any other drug information resource. It is the result of the consensus of 35 expert advisory panels representing medicine, dentistry, nursing, and pharmacy; and scientific, professional, consumer, and trade organizations. More than 800 volunteers who serve on USP's committees and panels review information before it is incorporated into the database, ensuring that it is complete, unbiased, and as free from commercial conflict as possible.

SUBJECT COVERAGE

Each monograph includes these important sections:

- Category (including indications)
- Medically Accepted Labeled and Unlabeled Uses
- Drug Interactions and Other Precautions
- Pharmacology/Pharmacokinetics
- Side/Adverse Effects
- Patient Consultation
- Dosing Information
- Dosage Form

TIPS

USE FILE 461

to monitor generic and brand name drug products, patient consultation, and DUR criteria.

USE MAP

to locate CAS® Registry Numbers in other databases, e.g., MAP NA TEMP.

USE RANK

S CL=CV?
RANK SH S1 CONT

DIALOG FILE DATA

Inclusive Dates: Same as current edition

Update Frequency: Quarterly

File Size:

1,236 monographs (covering more than 10,000 generic and brand name drugs)

CONTACT

USP DI® Volume I, Drug Information for the Health Care Professional is developed by Thomson MICROMEDEX. Questions concerning file content should be directed to:

Thomson MICROMEDEX

6200 South Syracuse Way, Suite 300

Greenwood Village, CO 80111-4740

Phone: 303-486-6400

Toll Free: 800-525-9083

Fax: 303-486-6464

E-Mail: mdx.info@thomson.com

File 461 **USP DI® Volume I, Drug Information for the Health Care Professional**

SAMPLE RECORD

DIALOG(R)File 461:USP DI(R) Vol. I
(c) 2004 Thomson Healthcare, Inc. All rts. reserv.

00001091
/TI BETA-ADRENERGIC BLOCKING AGENTS AND THIAZIDE DIURETICS (Systemic)

/NA, NA= This monograph includes information on the following:
Atenolol and Chlorthalidone; Bisoprolol and Hydrochlorothiazide (Not commercially available in Canada.); Metoprolol and Hydrochlorothiazide (Not commercially available in Canada.); Nadolol and Bendroflumethiazide; Pindolol and Hydrochlorothiazide (Not commercially available in the U.S.); Propranolol and Hydrochlorothiazide; Timolol and Hydrochlorothiazide.

Brand names:

/TN, TN=, /NA, NA= //Corzide//[Nadolol and Bendroflumethiazide]
//Inderide//[Propranolol and Hydrochlorothiazide]
//Inderide LA//[Propranolol and Hydrochlorothiazide]
//Lopressor HCT//[Metoprolol and Hydrochlorothiazide]
//Tenoretic//[Atenolol and Chlorthalidone]
//Timolide//[Timolol and Hydrochlorothiazide]
//Viskazine//[Pindolol and Hydrochlorothiazide]
//Ziac//[Bisoprolol and Hydrochlorothiazide]

Note: For a listing of dosage forms and brand names by country availability, see Dosage Forms section(s).

/CL, CL= CLASSIFICATION (Primary/Secondary): CV400/CV490

/TC CATEGORY: Antihypertensive.

Indications

Accepted
Hypertension (treatment) -- Beta-adrenergic blocking agent (beta-blocker) and thiazide diuretic combinations are indicated in the management of hypertension.

Fixed-dosage combinations generally are not recommended for initial therapy, but are utilized in maintenance after the required dose is established, in order to increase convenience, economy, and patient compliance. For additional information on initial therapeutic guidelines related to the treatment of hypertension, see //Appendix III.//

/PH PHARMACOLOGY/PHARMACOKINETICS
Physicochemical characteristics:

Molecular weight --
Atenolol: 266.34.
Bisoprolol fumarate: 766.97.
Bendroflumethiazide: 421.41.
Chlorthalidone: 338.76.
Hydrochlorothiazide: 297.73.
Metoprolol tartrate: 684.82.
Nadolol: 309.40.
Pindolol: 248.32.
Propranolol hydrochloride: 295.81.
Timolol maleate: 432.49.
(...)

/PS PRECAUTIONS TO CONSIDER

Note: In general, because of the similarity of effect and because the cardioselectivity of beta-1 blockers is relative, the same precautions, especially drug interactions and medical problems, apply to all beta-adrenergic blocking agents.

Cross-sensitivity and/or related problems
Patients sensitive to other sulfonamide-type medications,

SAMPLE RECORD (cont'd)

bumetanide, furosemide, or carbonic anhydrase inhibitors may be sensitive to thiazide diuretics also.
(...)

/AE SIDE/ADVERSE EFFECTS

Note: Signs and symptoms of overdose may include sudden bradycardia, hypotension, bronchospasm, cardiac failure, peripheral cyanosis, and seizures; hypoglycemia may occur rarely. In contrast, pindolol overdose may result in tachycardia and hypertension because of intrinsic sympathomimetic activity (ISA). Signs of overdose usually occur within 1 to 2 hours of ingestion.
(...)

/PC PATIENT CONSULTATION

As an aid to patient consultation, refer to //Advice for the Patient, Beta-adrenergic Blocking Agents and Thiazide Diuretics (Systemic).//

In providing consultation, consider emphasizing the following selected information (>> (=) major clinical significance):

Before using this medication

>> Conditions affecting use, especially:

Sensitivity to the beta-adrenergic blocking agent prescribed, or to any thiazide diuretic or other sulfonamide-type medications
(...)

/DO GENERAL DOSING INFORMATION

Fixed-dosage combinations generally are not recommended for initial therapy, but are utilized in maintenance therapy, after the required dose is established, in order to increase convenience, economy, and patient compliance.

The lowest effective dosage of thiazide diuretics should be utilized to minimize potential electrolyte imbalance and the reflex increase in renin and aldosterone levels.

Although plasma concentrations of beta-adrenergic blocking agents can be ascertained, there is not always a predictable relationship between plasma concentration and pharmacologic effects. Pharmacologic effects have been observed when plasma concentrations were not discernible. Therefore, titration of dosage with measurement of heart rate and blood pressure is used to guide therapy.
(...)

Selected Bibliography

The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)
Arch Intern Med 1993; 153(2): 154-83.

File 461 USP DI® Volume I, Drug Information for the Health Care Professional

SEARCH OPTIONS

BASIC INDEX

SEARCH SUFFIX	DISPLAY CODE	FIELD NAME	INDEXING	SELECT EXAMPLES
—	—	All Basic Index Fields	Word	S BETA(W)ADRENERGIC
/AE	AE	Side/Adverse Effects Section	Word	S BRONCHOSPASM/AE
/CC	CC	Controlled Substance Classification Section	Word	S SCHEDULE(W)IV/CC
/CL	CL	VA Classification Section ¹	Word	S CV100/CL
/DO	DO	General Dosing Section	Word	S ORAL(S)TWO(W)TIMES/DO
/NA	NA	Drug Name ^{1,2}	Word	S LOPRESSOR/NA
/PC	PC	Patient Consultation Section	Word	S HYPOGLYCEMIA/PC
/PH	PH	Pharmacology Section	Word	S LIPOPHILIC/PH
/PP	PP	Physical Properties Section	Word	S GAMMA(W)18/PP
/PS	PS	Precautions to Consider Section	Word	S CARBONIC(W)ANHYDRASE/PS
/TC	TC	Category Section	Word	S ANTIHYPERTENSIVE/TC
/TI	TI	Title ³	Word	S BETA(W)ADRENERGIC/TI
/TN	TN	Brand Name ^{1,3}	Word	S NADOLOL/TN

¹ Searchable in the Basic Index and in the Additional Indexes.

³ Also searchable as NA.

² Includes brand name (/TN and TN=).

ADDITIONAL INDEXES

SEARCH PREFIX	DISPLAY CODE	FIELD NAME	INDEXING	SELECT EXAMPLES
—	AZ	DIALOG Accession Number	Phrase	S CL=CV400
CL=	CL	VA Classification Code ¹	Word & Phrase	S NA=PROPANOLOL
NA=	NA	Drug Name ^{1,2}	Phrase	S NA=ALKA BUTAZOLIDIN
SH=	—	Section Heading	Phrase	S SH=PHARMACOLOGY
TN=	TN	Brand Name ^{1,3}	Word & Phrase	S TN=INDERIDE
UD=	—	Update	Phrase	S TN=INDERIDE LA S UD=9999

SPECIAL FEATURES

For command descriptions, enter HELP LIMIT, HELP SORT, HELP RANK, HELP MAP online.

SORT	TI	SORT S1/ALL/TI PRINT S5/5/1-24/TI
RANK	All phrase- and numeric-indexed fields in the Additional Indexes can be ranked.	RANK TN RANK SH S4
MAP	NA	MAP NA TEMP S1/1-10

PREDEFINED FORMAT OPTIONS

NO.	DIALOGWEB FORMAT	RECORD CONTENT
1	--	DIALOG Accession Number
2	--	Bibliographic Data (including Controlled Substance Section) and Category Section
3	Medium	Bibliographic Data (including Controlled Substance Section)
5	Long	Bibliographic Data (including Controlled Substance Section), Category Section, and Pharmacology Section
6	Free	Title and Word Count
7	--	Full Record
8	Short	Title, Word Count, and VA Classification
9	Full	Full Record
K	--	KWIC (Key Word In Context) displays a window of text; may be used alone or with other formats

OTHER OUTPUT OPTIONS

For an explanation, enter HELP TYPE, HELP UDF, HELP TAG online.

USER DEFINED FORMATS	Display codes listed in the Search Options tables can be used to customize output.	TYPE S3/TI,CC/1-5
TAG	Output can be displayed with tags identifying each display field.	TYPE S3/5/1-10 TAG
DIRECT RECORD ACCESS	If the accession number of a specific record is known, it can be used to display the record directly.	TYPE 00001091/5 DISPLAY 00000832/TI,CC PRINT 00000964/9

FOR ONLINE HELP:

See HELP FIELDS 461 for searchable fields; HELP FORMAT 461 for output formats; HELP LIMIT 461 for limits; HELP RATES 461 for cost information; HELP SORT 461 for sorts.